Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial

Emma del Carmen Macías-Cortés1,2*, Leopoldo Aguilar-Faisal1 and Juan Asbun-Bojalil1

Abstract

**Background:** The perimenopausal period refers to the interval when women’s menstrual cycles become irregular and is characterized by an increased risk of depressive symptoms. Use of homeopathy to treat depression is widespread but there is a lack of clinical trials about its efficacy in depression in peri- and postmenopausal women. Previous trials suggest that individualized homeopathic treatments improve depression. In classical homeopathy, an individually selected homeopathic remedy is prescribed after a complete case history of the patient. The aim of this study is to assess the efficacy and safety of the homeopathic individualized treatment versus placebo or fluoxetine in peri- and postmenopausal women with moderate to severe depression.

**Methods/design:** A randomized, placebo-controlled, double-blind, double-dummy, three-arm trial with a six-week follow-up study was designed. The study will be conducted in a public research hospital in Mexico City (Juárez de México Hospital) in the outpatient service of homeopathy. One hundred eighty nine peri- and postmenopausal women diagnosed with major depression according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (moderate to severe intensity) will be included. The primary outcome is change in the mean total score among groups on the 17-item Hamilton Rating Scale for Depression after the fourth and sixth week of treatment. Secondary outcomes are: Beck Depression Inventory change in mean score, Greene’s Scale change in mean score, response and remission rates and safety. Efficacy data will be analyzed in the intention-to-treat population. To determine differences in the primary and secondary outcomes among groups at baseline and weeks four and six, data will be analyzed by analysis of variance for independent measures with the Bonferroni post-hoc test.

(Continued on next page)
Discussion: This study is the first trial of classical homeopathy that will evaluate the efficacy of homeopathic individualized treatment using C-potencies versus placebo or fluoxetine in peri- and postmenopausal women with moderate to severe depression. It is an attempt to deal with the obstacles of homeopathic research due to the need for individual prescriptions in one of the most common psychiatric diseases.

Trial registration: ClinicalTrials.gov Identifier: NCT01635218.

Keywords: Perimenopause, Postmenopause, Depression, Homeopathy, Fluoxetine, Hamilton Rating Scale for Depression, Beck Depression Inventory

Background

Major depressive disorder (MDD) is the fourth most disabling medical condition worldwide and it is expected to be ranked second by the year 2020 [1,2]. It is typically recurrent and often chronic [3,4]. MDD is associated with high health care costs [5]. Women are approximately twice as likely to develop MDD as men [4,6]. The perimenopausal period refers to the interval when women's menstrual cycles become irregular, which generally occurs above the age of 40. Transition to menopause has long been considered a period of increased risk for depressive symptoms, as was demonstrated in the Harvard Study of Moods and Cycles, a population-based prospective study that examined the association between lifetime history of major depression and the decline in ovarian function [6]. According to the Stages of Reproductive Aging Workshop (STRAW), transition to menopause is the period that precedes menopause and it is characterized by variations in cycle length (>7 days different from baseline or ≥2 skipped cycles and an interval of amenorrhea ≥60 days) [7]. The postmenopausal stage is the period that continues after 12 months or more of amenorrhea. Depressive symptoms increase during the transition to menopause [8]. A significant inverse association of follicle stimulating hormone (FSH) with depressive symptoms provides strong corroborating evidence that the changing hormonal milieu contributes to dysphoric mood in this transition period [9]. With menopause, seric levels of FSH usually exceed 40 mIU/ml although, given the variability of individual hormone levels, the determination of menopausal status is generally made by clinical history rather than laboratory parameters. Furthermore, other hormones also change their serum concentrations. The decline in estrogen levels that is associated with menopause results in a wide range of symptoms, which include vasomotor symptoms (hot flushes and night sweats) [10].

The Hamilton Rating Scale of Depression (HRSD) and the Beck Depression Inventory (BDI) are two well-known standardized scales to assess depression severity used in trials worldwide. The Greene Climacteric Scale (GS) is also a standardized scale used in the Mexican population. It is intended specifically to be a brief and standard measure of core climacteric symptoms or complaints to be used for comparative and replicative purposes across different types of studies whether they are medical, psychological, sociological or epidemiological in nature. Three separate sub-scales measure vasomotor symptoms, somatic symptoms, psychological symptoms, and an additional probe is related to sexual function. Psychological symptoms can be further sub-divided to measure anxiety and depression [11,12].

Meta-analyses of antidepressant medications have reported only modest benefits over placebo treatment and, when unpublished trial data are included, the benefit falls below accepted criteria for clinical significance [13,14]. Specifically, a meta-analysis of clinical trial data submitted to the US Food and Drug Administration (FDA) revealed a mean drug-placebo difference in improvement scores of 1.8 points on the HRSD [15], whereas the National Institute for Clinical Excellence (NICE) used a drug-placebo difference of three points as a criterion for clinical significance when establishing guidelines for the treatment of depression in the UK. Antidepressants may be effective for severely depressed patients, but not for moderately depressed ones. Moreover, only about 50% of patients with MDD show a response (>50% reduction in baseline symptoms) and only about one in three attain remission (virtual absence of symptoms) within the first eight weeks of treatment [4,16-18].

Homeopathy is one of the most frequently used and controversial systems of medicine. It is based on the principle of similars; highly diluted preparations of substances that cause symptoms in healthy individuals are used to stimulate healing in patients who have similar symptoms when ill [19]. When a single homeopathic remedy is selected based on a patient's symptoms picture, it is called 'classical' homeopathy [20]. In classical homeopathy, the treatment consists of two main elements: the case history and the prescription of an individually selected homeopathic remedy. The purpose of the homeopathic case history is to ascertain the totality of signs and symptoms of each patient, enabling the selection of an individualized homeopathic medicine [21].

Homeopathic medicines are produced through sequential agitated dilutions in Decimal (D), Centesimal (C) or Quinquagintamillesimal (Q or LM) potencies [21].
C-potencies are prepared by diluting a drop of a parent substance in 99 drops of ethanol followed by agitation of the solution (1 C). This procedure is repeated in consecutive agitated dilutions (2 C, 3 C, 4 C, and so on). Generally, high potencies are prescribed for mental symptoms.

Use of homeopathy to treat psychiatric and menopausal problems is widespread, and the need for more high-quality controlled trials has been identified [22,23]. Meta-analyses and systematic reviews have drawn mixed conclusions as to whether homeopathy is more effective than placebo in general medicine [20,24-28]. The database on studies of homeopathy and placebo in psychiatry is very limited, but results do not preclude the possibility of some benefit. Homeopathy efficacy was found for fibromyalgia and chronic fatigue syndrome, for example [22].

Bordet et al. conducted a multi-national prospective non-comparative observational study of homeopathic treatments for hot flushes and suggest that further investigation is justified [29]. Jacobs et al. conducted a randomized, double-blind study versus placebo performed over one year with 83 women suffering from breast cancer; patients received either individualized homeopathic treatment or a homeopathic complex or a placebo. This study did not show any significant difference between the three patient groups relative to the severity and frequency of hot flushes although there was a trend in the ‘individualized homeopathic treatment’ group during the first three months of the study [30]. Although depression is one of the most common symptoms in peri- and postmenopause, there is no controlled study of the homeopathic use of individualized treatment in depressive disorders in women at this stage.

Recently, results from a randomized, controlled, double-blind trial indicated that individualized homeopathic Q-potencies were non-inferior to the antidepressant fluoxetine in a sample of patients with moderate to severe depression [21,31]. Responder rates (defined as a decrease of at least 50% from baseline on the Montgomery and Asberg Depression Rating Scale) were higher (homeopathy 84.6%, fluoxetine 82.8%) than those usually found for antidepressants in clinical trials (43% to 75%) [21,31]. However, the efficacy of the individualized homeopathic C-potencies for peri- and postmenopausal women with depression has not been investigated.

**Aims**

The primary aim of the study is to assess the efficacy of individualized homeopathic treatment (IHT) versus fluoxetine and placebo, and fluoxetine versus placebo using the BDI and GS's score; and (2) to determine the safety of IHT versus fluoxetine and placebo, and fluoxetine versus placebo in peri- and postmenopausal women with moderate to severe depression.

**Methods/design**

**Study design**

The study will be a randomized, placebo-controlled, double-blind, double-dummy, three-arm parallel, superiority trial with a six-week study duration.

**Study setting**

The study will be conducted in a public, academic and research hospital in Mexico City, the Juárez de México Hospital (JMH), which belongs to the Ministry of Health (MoH), the central authority in charge of health policies and design programs. The MoH provides health care to people without social security. JMH is an academic specialized hospital. Homeopathy is part of the National Health System regularized by the MoH. The outpatient service of homeopathy was established in JMH in 2004 and provides health care for climacteric stage women daily.

**Participant recruitment**

The recruitment methods will include advertisements through the internet, local media and community groups, and liaisons with general practitioners, gynecologists, psychologists and allied health professionals. Poster with information about the study protocol will be posted at the study site; brochures will be distributed among the hospital population. Participants are currently being recruited starting in March 2012. The study is planned to end in December 2013.

**Eligibility criteria**

The entry criteria for the study will be: (1) 40 to 65 years of age; (2) diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV); (3) moderate to severe depression according to the 17-item HRSD (14 to 24 score); (4) no current use of homeopathic treatment for depression or antidepressants or anxiolytic drugs for three months prior to study entry; (5) not taking psychotherapy for at least three months before screening; (6) no use of estrogens or other medications known to affect ovarian function for at least three months before screening; (7) early transition to menopause, defined by a change in cycle length of seven days or longer in either direction from the participant's own baseline for at least two cycles; or late transition to menopause, defined as three to eleven months of amenorrhea; (8) postmenopausal stage defined by 12 months or more of amenorrhea; and (9) capability and willingness to give informed consent and to comply with the study procedures.
Exclusion criteria include: (1) pregnancy or breastfeeding; (2) other psychiatric disorders different from moderate to severe depression (severe depression, schizophrenia, psychotic disorders, bipolar affective disorders, suicide attempt, and so on); (3) alcohol or other substance abuse; (4) known allergy to fluoxetine; and (5) cancer or hepatic diseases.

**Types of interventions**

After inclusion, patients will be randomly assigned to either one of three groups illustrated in Figure 1: (1) IHT plus fluoxetine dummy-loaded; (2) fluoxetine (20 mg/day) plus IHT dummy-loaded; and (3) fluoxetine placebo plus IHT placebo.

The selection of the individualized remedy will be carried out after the case history by a certified medical doctor, specialized in homeopathy with 18 years’ experience in classical homeopathy. The case history will be based on Hahnemann’s methodology described in paragraphs 83 to 104 of Organon of Medicine, 6th edition. A complete medical history with clinical examination will also be done. All patients will have a full homeopathic case-taking including the collection of all the facts pertaining to the patient which may help in determining the totality of the symptomatology: past and present physical and emotional symptoms, family environment since childhood, stressful life events, marital satisfaction. The symptoms will be organized by hierarchy: mental, general and physical. In the first place, the strategy to choose the individualized remedy will be based on the most characteristic and clear mental symptoms. Secondly, general symptoms will be taken into account. A computerized version of the Synthesis Homeopathic Repertory 9.1 (Radar version 10) will be used to facilitate the prescription. Only one remedy will be prescribed at a time but it could be changed at every follow-up according to the patient’s symptoms.

C-potencies will be provided by Laboratorio Similia (Mexico City) and are manufactured according to the Mexican Homeopathic Pharmacopoeia and Hahnemann’s methodology. Each individualized homeopathic remedy will be prescribed in C-potencies (Appendix 1). Higher initial potencies will be tried, ranging from 30 to 200 C. The factors that influence the selection of the potency will include: clarity of mental symptoms, patient’s vitality and sensitivity, nature and kingdom (source) of medicine, chronicity and presence of any pathological disorder. A single dose of the individualized homeopathic remedy selected will be dissolved in a 60 ml bottle of 30% alcohol-distilled water. Patients will receive 15 drops PO two times per day following agitation for 10 days, plus fluoxetine-dummy loaded prescribed PO daily. A double-dummy technique with matching placebos for each active treatment will be applied, thus both placebos will seem identical to their corresponding verum formulations. Follow-up will be at weeks four and six after the first clinical interview.

Patients in the fluoxetine group will receive 20 mg/day PO plus IHT-dummy loaded. IHT-dummy loaded will be repeated at week four. Capsules of a generic fluoxetine will be provided by Laboratorio Similia (Mexico City). Placebo capsules will contain sucrose micro globules. Homeopathic placebo bottles will be filled with the same amount of 30% alcohol-distilled water. Patients will receive 15 drops PO of this solution two times per day following agitation for 10 days. The homeopathic placebo will be repeated at week four.

The third group will receive both fluoxetine and IHT placebos, as previously described.

**Criteria for discontinuing or modifying allocated interventions**

Some adverse effects have been observed during fluoxetine treatment: lack of interest in sex, sexual dysfunction, nausea, insomnia, somnolence, anorexia, anxiety, asthenia, tremor, allergic skin reactions. If they are serious and/or result in interruption of treatment, they will be reported as adverse events.

During the IHT participants could have one of these reactions: (1) temporary intensification of symptoms before the condition improves, which is named ‘homeopathic aggravation.’ If it occurs at all it is usually mild and simply an indication that the body is resolving the problem in a natural and healthy way. If aggravation is too distressing it will be lessened by using frequent doses of the same remedy in a lower potency; (2) improving symptoms without aggravation; and (3) the appearance of new symptoms different from those on which the prescription was based. They will be reported as adverse events. They are rarely serious, but in that case, the IHT’ will be stopped. If the participant experiences the same symptoms of the remedy, the corresponding antidote will be prescribed.

Each participant will receive a report form on which to write daily any adverse event observed during the trial.
duration. Study participants will be retained in the trial whenever possible to enable follow-up data collection and prevent missing data.

**Adherence to interventions**

To enhance the validity of the data, participants will return the unused capsules and bottles at each follow-up visit. Unused capsules will be counted and recorded on the appropriate case report form. Participants will be asked about any problems they are having taking their study treatment.

**Concomitant interventions**

Some medications are prohibited during the study duration: triptans, tramadol, anxiolytic drugs, other serotonergic agents or antidepressants, as well as hormone replacement therapy. Psychotherapy is also forbidden during the study duration. Medication for diabetes and hypertension is allowed. The rescue intervention in case of a lack of efficacy in the IHT and placebo groups will be fluoxetine 20 mg/day; in the fluoxetine group, the rescue medication will be sertraline 25 mg/day.

**Participant retention**

Plans to promote participant retention and complete follow-up will include: scheduling appointments and contacting patients by telephone.

**Outcomes**

The primary efficacy outcome is the change from baseline in mean total depression score using the 17-item version of the HRSD at weeks four and six. The severity of symptoms will be assessed by a blinded investigator (clinical psychologist) from the JMH. The secondary outcomes are: change from baseline in mean total depression score using BDI (a self-reported scale) at weeks four and six; responder rates (response rate: decrease of 50% or more from baseline score; remission rate: HRSD ≤7). The number and severity of all adverse events and homeopathic aggravations during the study period and 15 days after the final dose will be collected to determine the safety of fluoxetine and homeopathic medicines. An adverse event will be defined as any untoward medical occurrence in a subject without regard to the possibility of a causal relationship. Adverse events will be collected after participants have given consent and enrolled in the study and 15 days after study completion.

**Randomization**

Participants are simple randomized in a 1:1:1 ratio using a computer-generated random allocation sequence, by a statistician not further involved in the study. Participants will be assigned in sequential order to the treatment groups. The randomization list will be kept strictly confidential.

**Allocation**

**Concealment mechanism and implementation**

The principal investigator will enroll participants. Following inclusion, all patients will go through a full homeopathic case-taking and will receive a prescription of the individualized homeopathic medicine. Only one-third of the participants will actually receive a prescription. The research pharmacist will randomly deliver the treatment according to the allocation sequence in one of the three groups previously described. The randomization list will be sent to the research pharmacist at the start of the study. In case of emergency interventions, clinical worsening or adverse events, the pharmacist will inform the homeopathic doctor if the individual patient is taking homeopathy, fluoxetine or placebo, without disclosing the code.

**Blinding**

Participants, the homeopathic doctor, the psychologist and the statistician will remain blinded to the identity of the three treatment groups until the end of the study. The psychologist will assess the severity of the symptoms and will keep the HRSD scores strictly confidential in a closed envelope at every follow-up until the end of the study.

**Sample size calculation**

Sample size calculation was estimated using G*Power (available at the University of Dusseldorf: http://www.psych.uni-dusseldorf.de/aap/projects/gpower/). The sample size calculation is based on a previous study protocol for a randomized controlled trial of homeopathy for depression published by Adler et al. [21]. We assumed that verum treatment is better than placebo by 2.7 ± 6.0 (mean ± standard deviation) HRSD score points after six weeks [21], corresponding to an effect size = 0.45 (largest difference between any two groups to be detected/expected within group standard deviation = diff/de). To detect an effect size = 0.45, in a three-group design (1:1:1), using F-Test, with a 5% risk of type 1 error (α) and 83% power, 63 patients per group are required considering also a 10% dropout rate.

**Data collection**

Study data will be collected at baseline, at every follow-up and 15 days after the completion of the study. Data will be collected from different sources: medical records, questionnaires (HRSD, BDI, GS) and report forms where participants will write daily any adverse event.
Data management

All data will be entered electronically on data sheets designed for the study. The original study forms will be entered and kept on file at the JMH. Participant files are to be stored in numerical order in a secure and accessible place and manner. Participant files will be maintained in storage for a period of five years after completion of the study. All forms related to the study data will be kept in locked cabinets. Access to the study data will be restricted. A complete back-up of the data will be performed every month.

Statistical analysis

All patients under randomization will be included in the primary efficacy population (intention-to-treat population), regardless whether or not they adhered to the treatment protocol or provided complete data sets. Only patients who withdraw their consent to use their personal data will be excluded from the analysis. The flow of participants through the trial will be presented in a Consolidate Standards of Reporting Trials (CONSORT) diagram.

First, the three groups will be compared in order to verify that there are no significant differences among them at baseline to confirm they are comparable after randomization. Demographic characteristics will be summarized using means and standard deviation for continuous data (that is, age) and relative frequencies for qualitative data (that is, marital status, comorbidities). The baseline demographic characteristics among groups will be compared with the use of the chi square test or one-way ANOVA as required.

We will compare: (1) IHT versus placebo; (2) fluoxetine versus placebo; and (3) IHT versus fluoxetine. The main statistical analysis will compare primary and secondary outcome measurements among groups at weeks four and six. The primary outcome (change in mean HRSD score) and secondary outcomes (change in mean BDI and GS scores) among groups at baseline and weeks four and six, will be analyzed by one-way ANOVA to provide a statistical test of whether or not the means of the three groups are all equal. The statistically significant one-way ANOVA result ($P < 0.05$) suggests rejecting the global null hypothesis $H_0$ (that the means are the same across IHT, fluoxetine and placebo groups). The Bonferroni post-hoc test will be used to determine which means differ among the groups. Responder rates will be compared among the groups using the chi square test. Statistical significance will be set at $P < 0.05$ level for all analysis. Missing data will be handled by sensitivity analysis.

All patients who received at least one dose of the study drugs will be considered in the safety analysis. Adverse events will be translated to Medical Dictionary for Regulatory Activities terms (MeDRa terms), quantified and compared among the groups using the chi square test. Homeopathic aggravation will be compared among the groups also using the chi square test.

Auditing

The Research and Ethics Committee of JMH, which is not involved in the study, will review the trial process every three months.

Confidentiality

All study-related information will be stored securely at the study site. Participants’ study information will not be released outside of the study without the written permission of the participant.

Regulatory and ethical approval

The trial protocol has been reviewed and approved by the Research and Ethics Committee of the Juárez de México Hospital (Submission Nº HJM 2030/12-A). This study is in compliance with the Helsinki Declaration and with the International Conference on Harmonisation (ICH) – Good Clinical Practice. Prior to undertaking any study related procedures, each participant will receive a verbal and written explanation of study aims, methods, potential hazards, and benefits from investigators and will provide written informed consent.

Post-trial care

In the case of adverse events and after the completion of the study, participants may continue receiving health care at JMH.

Discussion

For the first time this study evaluates both the specific effect of IHT using C-potencies versus fluoxetine and placebo in peri- and postmenopausal women with moderate to severe depression. Besides comparing homeopathic medicines versus placebo, the fluoxetine-arm will give more useful information about the effect of IHT versus an efficacious treatment for depression in a randomized controlled trial. It is an attempt to deal with the obstacles of homeopathic research due to the need of individual prescriptions in one of the most common psychiatric disorders. Homeopathy is frequently prescribed for climacteric symptoms including depression as it has been proven in some observational studies, but there is a lack of high-quality trials to prove its efficacy. This study protocol is based on: (1) CONSORT guidelines for reporting randomized trials with parallel groups; (2) the reporting data on homeopathic treatments (RedHot) supplement to CONSORT [32,33]; and (3) the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 guidance for protocols of clinical trials [34].

It has been reported that the homeopathic consultation is in itself a therapeutic intervention working independently of the prescribed remedy [35], so all study participants will go through the same full homeopathic case-taking regardless of group allocation. Because placebo interventions are associated with mean response or remission rates of 35% [36,37], this trial includes a placebo-arm, so placebo effect can be ruled out.

Gibbons et al. reported that patients in all age and antidepressant groups have significantly greater improvement relative to placebo controls; and fluoxetine has been proven to be efficacious for depression in adults after six weeks of treatment [38], so it is expected that the fluoxetine-arm will result in significant differences versus placebo in this study. However, Kirsch et al. reported that, at present, it is becoming more difficult to prove that antidepressants actually work better than placebo in moderate to severe depression. It also has to be taken into consideration that the antidepressant-placebo difference seems to be smaller in the trials with moderately depressed participants [13]. Therefore, a fluoxetine-arm will allow us to detect if in Mexican women in the climacteric stage with moderate to severe depression, the difference in HRSD score between fluoxetine and placebo is as small as it has been shown in some meta-analysis [13].

Otherwise, different scenarios can result if no significant differences between IHT and placebo groups are found. In classical homeopathy, recovery requires the prescription of the individualized remedy at the adequate potency and dosage, so this is an important factor to be taken into consideration during the trial process because results may be biased. A negative result could be due to a mistaken election of the remedy and not because the IHT is inefficacious. Follow-up duration is also important. The selection of a suitable, individualized homeopathic medicine will not always be accomplished during six weeks of treatment, especially under double-blind conditions [21]. It has not been proved that six weeks of IHT is enough time to find a clinically relevant response in climacteric women with depression. In routine homeopathic consultation, a patient may require more than six weeks to recover from depression. However, for ethical reasons a longer follow-up is not possible because of the placebo group. Furthermore, homeopathic prescriptions may need to be modified depending on a patient’s individual response after homeopathic treatment is initiated. Once again, this could be problematic under double-blind conditions.

For ethical reasons women with severe depression will be excluded, so data of this trial will be able to prove an effective treatment in Mexican climacteric women with moderate to severe depression. Depression severity will be scored by the 17-item HRSD, which is a standardized instrument that has been used in many other clinical trials for depression. Another self-administered instrument, the BDI will also be used, so the results of the study might provide useful information in clarifying the controversy over the efficacy of homeopathy in depression. Use of these standardized instruments enables us to compare results with other trials published worldwide.

**Trial status**

Participant recruitment began in March 2012.

**Appendix 1**

C-potencies will be stored at Juárez de México Hospital. Medicines not listed can optionally be ordered and prescribed, as needed.

Actaea racemosa, Aurum metallicum, Calcarea carbonica, Conium maculatum, Coffea cruda, Gelsemium sempervirens, Glonoinum, Helonias dioica, Kali carbonicum, Kali phosphoricum, Lachesis trigonocoevalus, Lilium tigrinum, Lycopodium clavatum, Murex purpurea, Natrum muriaticum, Nux vomica, Phosphoricum acidum, Phosphorus, Platina, Pulsatilla nigricans, Sanguinaria canadensis, Sepia officinalis, Spigelia, Staphysagria.

**Abbreviations**

ANOVA: analysis of variance; BDI: Beck Depression Inventory; CONSORT: Consolidated Standards of Reporting Trials; C-potencies: centesimal potencies; D-potencies: decimal potencies; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, fourth edition; FSH: follicle stimulating hormone; GS: Greene Climacteric Scale; HRSD: Hamilton Rating Scale for Depression; ICH: International Conference on Harmonisation; IHT: individualized homeopathic treatment; JMH: Juárez de México Hospital; MDD: major depressive disorder; MeDrA terms: Medical Dictionary for Regulatory Activities Terms; NICE: National Institute for Clinical Excellence; Q or LM potencies: quinquagintamillesimal; STRAW: Stages of Reproductive Aging Workshop.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ECMC, JAB and LAF participated in the design of the study, ECMC and JAB reviewed and discussed data for moderate depression, fluoxetine and homeopathy. ECMC, JAB and LAF made important contributions to the design of the trial, were substantially involved in drafting and revising the manuscript, and gave final approval of the submitted version of the document. All authors read and approved the final manuscript.

**Authors’ information**

ECMC is a Homeopathic MD, MSc of Escuela Superior de Medicina, Instituto Politécnico Nacional. She was responsible for initiating the outpatient service of homeopathy in Juárez de México Hospital. JAB and LAF are full time professors and investigators of Escuela Superior de Medicina, Instituto Politécnico Nacional.

**Acknowledgements**

We thank Gustavo Aguilar-Velázquez, MD, PhD, Laboratorio Similia for donating kindly and unconditionally C-potencies, fluoxetine and placebos; Imelda Hernández-Marín, MD, Department of Biology of Reproduction, Juárez de México Hospital, who provided technical and medical advice in the study design. We also thank María Elena Monterde-Corone, MSc, who will provide advertising on the website www.homeopatía.com.mx.
References

1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER: Funding. J Clin Psychiatry 1991, 52:459–466.
2. Murray CJ, Lopez AD: The global burden of disease. Lancet 1996, 347:149–229.
3. Keeler RC, Berghard P, Dorrer O, Jin R, Koretz D, Menkargas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2002, 59:851–860.
4. Williams LM, Rush AJ, Kaslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, Schatzberg AF, Gorden E: International study to predict optimized treatment for depression (ISOT-D): a randomized clinical trial: rationale and protocol. Trials 2011, 124.
5. Simon GE, Von Korff M, Barlow W: Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995, 52:850–858.
6. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL: Risk for new onset of depression during menopausal transition. Arch Gen Psychiatry 2006, 63:385–390.
7. Halle GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Frasier IS: Endocrine features of menstrual cycle in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) Staging System. J Clin Endocrinol Metab 2007, 92:3060–3067.
8. Freeman EW, Sammel MD, Hui L, Nelson DB: Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006, 63:375–382.
9. Freeman EW, Sambell MD, Liu L, Garcia CR, Nelson DB, Hollander L: Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004, 61:62–70.
10. Rapkin AJ: Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007, 196:97–106.
11. Greene JG: Constructing a standard climacteric scale. Maturitas 1998, 29:25–31.
12. Hernández-Valencia M, Cordova-Pérez N, Basutto L, Saucedo R, Vargas C, Vargas A, Ruiz M, Manuel L, Zárate F: Frequency of symptoms of the climacteric syndrome. Ginecol Obstet Mex 2010, 78:252–257. Spanish.
13. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5:e645. doi:10.1371/journal.pmed.0050045.
14. National Institute for Clinical Excellence: Depression: Management of Depression in Primary and Secondary Care. Clinical Practice Guideline. London: No. 23, 670.
15. Kirsch I, Moore TJ, Scoboria A, Nicholls S: The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prev Treat 2002, Sart 23.
16. Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996, 19:179–200.
17. Frank E, Prien R, Jarrrett RB, Keller MB, Kupfer DJ, Lavon PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991, 48:851–855.
18. Trivedi MH, Rush AJ, Woeniwski SR, Nierenberg AA, Warden D, Zit RW, Nordquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balabanis GR, Fava M, STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28–40.
19. Jonus W, Jacobs J: Healing with Homeopathy. New York: Warner; 1996.
20. Linde K, Clausius N, Ramirez G, Melchart D, Ernst E: The efficacy of homeopathy. A meta-analysis of placebo-controlled trials. Lancet 1997, 350:834–843.
21. Adler U, Krüger S, Teut M, Lützke R, Bartisch I, Schützler L, Melcher F, Willrich SN, Linde K, Witt CM: Homeopathy for depression – DEP-HOM: study protocol for randomized, double-blind, placebo-controlled, four armed study. Trials 2011, 12:43.
22. Dawson JR, Crawford C, Yes JA, Jonas WB: Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J Clin Psychiatry 2011, 72:795–805.
23. Freeman MP, Michouillon D, Tedeschi E, Goodness T, Cohen LS, Fava M, Papakostas GI: Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry 2010, 71:682–688.
24. Jonas WB, Kapchuck YJ, Linde K: A critical overview of homeopathy. Ann Intern Med 2003, 138:393–399.
25. Linde K, Melchart D: Randomized controlled trials of individualized homeopathy: a state-of-the-art review. J Altern Complement Med 1998, 4:371–388.
26. Ernst E: Homeopathy: what does the “best” evidence tell us? Med J Aust 2010, 192:458–460.
27. Spengler M, Hübler-Müntener K, Narley M, Jüni P, Dörg S, Steine JA, Pehswan D, Egger M: Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy. Lancet 2005, 366:762–763.
28. Lüdecke R, Rutten AT: The conclusions on the effectiveness of homeopathy highly depend on the set of analyzed trials. J Clin Epidemiol 2008, 61:197–1204.
29. Bondet MF, Colas A, Marion J, Masson JL, Trichard M: Treating hot flushes in menopausal women with homeopathic treatment: results of an observational study. Homeopathy 2008, 97:10–15.
30. Jacobs J, Hermann P, Heron K, Olsen S, Vauthers L: Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled study. J Altern Complement Med 2005, 11:21–27.
31. Adler U, Paiva NW, Cesar AT, Adler MS, Molina A, Padula AE, Cali HM: Homeopathic individualized Q-potencies versus fluoxetine for moderate to severe depression: double-blind, randomized non-inferiority trial. Evid Based Complement Altern Med 2011, 2011:250128. doi:10.1093/ecam/nep114.
32. Schulz KF, Altman DG, Moher D: CONSORT Group: CONSORT 2010 statement updated guidelines for reporting parallel group randomized trials. PLoS Med 2010, 7:e1000251. doi:10.1371/journal.pmed.0050045.
33. Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H: Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. J Altern Complement Med 2007, 13:19–23.
34. Chan AW, Teitzlff J, Götzsche PC, Altman DG, Mann H, Berlin JA, Dickerson K, Hoptgartson A, Schulz KF, Parulekar WR, Kliexa-Jeric K, Laupacis A, Moher D: SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013, 346:e7496. doi:10.1136/bmj.e7496.
35. Thompson TD, Weiss M: Homeopathy – what are the active ingredients? An exploratory study using the UK Medical Research Council’s framework for the evaluation of complex interventions. BMC Complement Altern Med 2006, 6:37.
36. Mulrow CD, Williams JW, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, Cornell J, Stann K: Efficacy of new medicines for treating depression in primary care patients. Am J Med 2000, 108:54–64.
37. Dawson MV, Michalak EE, Anderson JE, Lam RW: Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. BMC Fam Pract 2004, 5:819.
38. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ: Who benefits from antidepressants? Synthesis of 6-week patient-level outcomes from double-blind placebo controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012, 69:572–579.

doi:10.1186/1745-6215-14-105

Cite this article as: Macías-Cortés et al.: Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMEDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial. Trials 2013 14:105.